Payment overview · 2025
General Payments
$230.98
10 reported records · 7 companies
Healthcare provider profile · identity verified
Jose Ignacio Lopez, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · TAMPA, FL · NPI 1942307681
Verified facts
What the public records show
CMS Open Payments records show Jose Ignacio Lopez, M.D received $230.98 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.07 | 29.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.61 | 17.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.46 | 14.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.08 | 12.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $25.54 | 11.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.62 | 8.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.60 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $230.98 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 607 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 480 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 417 | 136 |
| Gabapentin | Gabapentin | 336 | 95 |
| Losartan Potassium | Losartan Potassium | 324 | 97 |
| Alprazolam | Alprazolam | 315 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 88 |
| Metformin Hcl | Metformin Hcl | 276 | 81 |
| Lisinopril | Lisinopril | 250 | 72 |
| Famotidine | Famotidine | 197 | 63 |
| Montelukast Sodium | Montelukast Sodium | 186 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 50 |
| Temazepam | Temazepam | 165 | 39 |
| Omeprazole | Omeprazole | 164 | 58 |
| Finasteride | Finasteride | 160 | 50 |
| Glipizide Er | Glipizide | 153 | 33 |
| Vascepa | Icosapent Ethyl | 152 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 44 |
| Allopurinol | Allopurinol | 141 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 44 |
| Meloxicam | Meloxicam | 129 | 64 |
| Eliquis | Apixaban | 121 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 38 |
| Donepezil Hcl | Donepezil Hcl | 111 | 33 |
| Carvedilol | Carvedilol | 110 | 40 |
| Sertraline Hcl | Sertraline Hcl | 105 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 61 |
| Cefdinir | Cefdinir | 99 | 63 |
| Baclofen | Baclofen | 97 | 46 |
| Ciclopirox | Ciclopirox | 97 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 17 |
| Simvastatin | Simvastatin | 95 | 28 |
| Furosemide | Furosemide | 93 | 28 |
| Azithromycin | Azithromycin | 92 | 72 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 92 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 59 |
| Lorazepam | Lorazepam | 90 | 19 |
| Celecoxib | Celecoxib | 82 | 44 |
| Mupirocin | Mupirocin | 81 | 52 |
| Ketoconazole | Ketoconazole | 79 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 24 |
| Potassium Chloride | Potassium Chloride | 75 | 18 |
| Meclizine Hcl | Meclizine Hcl | 72 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 66 | 37 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 66 | 52 |
| Atenolol | Atenolol | 63 | 14 |
| Valsartan | Valsartan | 63 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 43 |
| Ibandronate Sodium | Ibandronate Sodium | 57 | 16 |
| Glipizide | Glipizide | 56 | 13 |
| Methylprednisolone | Methylprednisolone | 56 | 47 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 54 | 13 |
| Trazodone Hcl | Trazodone Hcl | 53 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Pregabalin | Pregabalin | 51 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 13 |
| Fenofibrate | Fenofibrate | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 47 | 13 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Lidocaine | Lidocaine | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 11 |
| Jardiance | Empagliflozin | 42 | 11 |
| Prednisone | Prednisone | 41 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 13 |
| Ondansetron Odt | Ondansetron | 38 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Folic Acid | Folic Acid | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Pentoxifylline | Pentoxifylline | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Levemir | Insulin Detemir | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | 11 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 18 | 13 |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $230.98 · 10 records | Novo Nordisk Inc | AIRSUPRA, FARXIGA, GEMTESA, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error